United States: "Investment" Narrowly Construed Under NAFTA In Apotex v. United States

A recent decision provides a narrow interpretation of "investment" under NAFTA Chapter Eleven

In a recent NAFTA Investor-State claim brought against the United States by Apotex Inc., Canada's largest producer of generic drugs, the Tribunal upheld the United States' preliminary objections to jurisdiction on the grounds, inter alia, that the company's efforts to win approval for generic drugs in the United States market did not make it an "investor" under Article 1139 of NAFTA Chapter Eleven.  In Apotex Inc. v. The Government of the United States of America, Award on Jurisdiction and Admissibility (14 June 2013), the Tribunal held that significant expenses incurred in: (i) seeking Food and Drug Administration ("FDA") approval; (ii) purchasing materials and ingredients in the United States intended for the manufacture of products abroad (in this case in Canada); and (iii) conducting litigation and establishing an agent in the United States for the purpose of corresponding with and making submissions to the FDA, were all insufficient to qualify as an "investment" under the treaty.  This award sheds further light on the precise meaning of the term "investment" under NAFTA and confirms that, as with other provisions of NAFTA Chapter Eleven, investors must surmount a high jurisdictional threshold in order to bring claims before a NAFTA tribunal.    

Apotex alleged in the arbitration that its rights were violated by the United States in breach of NAFTA Articles 1102 (obligation to accord national treatment to foreign investments), 1105 (obligation to accord fair and equitable treatment to foreign investments) and 1110 (obligation not to expropriate without payment of fair compensation).  Apotex claimed that it was subject to mistreatment by the United States, its agencies (in particular the FDA) and its Federal Courts in the course of the company's efforts to bring generic versions of the anti-depressant drug Zoloft (to be marketed as Sertraline by Apotex) and the anti-cholesterol drug Pravachol (to be marketed as Pravastatin by Apotex) to market in that country.  In particular, the Sertraline claim arose out of three United States Federal Court decisions pertaining to Apotex's application for FDA approval of its generic drug.  The Pravastatin claim arose out of a decision by the FDA and three decisions of the United States Federal Courts, pertaining to Apotex's application for FDA approval of its generic drug.

The United States objected to the jurisdiction of the NAFTA Tribunal on the grounds, inter alia, that Apotex did not qualify as an "investor" which had made an "investment" in the United States for the purposes of NAFTA Article 1139 (which Article contains the definitions of "investment" and "investor of a Party").     

Apotex argued in response that: (i) it had invested millions of dollars in developing its products and preparing and filing its submissions to the United States' FDA; (ii) the sole purpose of Apotex's development and submission of the FDA application was to obtain FDA approval to commercialize its products in the United States; (iii) Apotex's FDA application was manifestly a U.S. investment (i.e. property, tangible or intangible, acquired in the expectation or used for the purpose of economic benefit or other business purposes); (iv) Apotex had made substantial commitments of capital and other resources towards economic activity in the United States, including the purchase of raw materials from United States suppliers for its Pravastatin manufacturing process; and (v) Apotex had designated its United States affiliate and distributor as its United States agent for FDA regulatory purposes, as well as designating an agent for service of process in the United States, thus consenting to jurisdiction and suit there.      

The Tribunal addressed Apotex's defenses to the United States' main jurisdictional objection and found that, "each of the specific activities and expenses relied upon by Apotex simply supported and facilitated its Canadian-based manufacturing and export operations," meaning that such expenditures could not count as investments in the United States.  Further, the Tribunal held that Apotex's activities with respect to the contemplated sales of its Sertraline and Pravastatin products in the United States were "those of an exporter, not an investor" and as such were not protected by NAFTA's provisions on national treatment.  Similarly, the Tribunal held that the purchase of materials and ingredients in the United States could not count as an investment as they were intended for the manufacture of products abroad.  Finally, the Tribunal found that conducting litigation in the United States and establishing an agent in the country to assist with FDA submissions, constituted an ordinary part of doing business and did not amount to an investment.  Consequently the Tribunal held that no "investment" had been made by Apotex in the territory of the United States within the scope of NAFTA Chapter Eleven and that Apotex itself did not therefore qualify as an "investor" under the treaty.  This finding was sufficient for the Tribunal to dismiss Apotex's claims in their entirety.  

The United States had, in addition to the above jurisdictional objection, argued that: (i) Apotex had failed to pursue available remedies within the United States Court system with respect to its Pravastatin claim, such that the judicial acts complained of lacked sufficient finality to form the basis of claims under NAFTA Chapter Eleven; and (ii) the time bar in NAFTA Article 1116(2) precluded Apotex's allegation in its Pravastatin claim that the FDA's letter decision of 11 April 2006 (determining that a 180-day exclusivity period had not been triggered) itself constituted a violation of Articles 1102, 1105 and 1110 of NAFTA.  Despite having already dismissed Apotex's claims in their entirety, the Tribunal went on to address these additional jurisdictional objections, finding in favor of the United States in both instances.  Particularly noteworthy is the Tribunal's rejection of  Apotex's argument that it had satisfied the requirement to exhaust local legal remedies because appealing to the United States Supreme Court would have been "obviously futile," based primarily on the small number of cases that this Court entertains each year.  The Tribunal held that to accept such an argument would be, "to write the US Supreme Court out of the exhaustion of remedies rule in almost all cases."   The tribunal, having rejected Apotex's jurisdictional defenses, ordered the company to pay the United States' legal costs as well as the costs of the arbitration. 

It is noteworthy that Apotex chose, for unknown reasons, not to advance three arguments that could conceivably have resulted in it overcoming the jurisdictional objections of the United States.  First, the award focused on investments the company claimed it had made in the U.S., as opposed to investments that it intended to make in the country. Apotex's apparent failure to focus on the investments it intended to make is surprising given that the company's attempts to bring new drugs to market in the United States could arguably be interpreted as Apotex "establishing, acquiring" and "expanding" its investments in the country.  A "pre-establishment" argument with respect to Apotex's national treatment claim under NAFTA Article 1102(2) (which states that, "Each Party shall accord to investments of investors of another Party treatment no less favorable than that it accords, in like circumstances, to investments of its own investors with respect to the establishment, acquisition, expansion, management, conduct, operation and sale or other disposition of investments") might arguably have stood a greater chance of success than the more straight-forward investment argument advanced by Apotex.  Second, the Claimant could also have argued that its activities in the U.S. were covered by NAFTA Article 1139 (which states that, "investor of a Party means a Party or state enterprise thereof, or a national or an enterprise of such Party, that seeks to make, is making or has made an investment.")  As both NAFTA Articles 1102(1) and 1103(1) explicitly extend treaty protection to "investors" as well as "investments", Apotex could well successfully have argued that its attempts to sell generic drugs in the U.S. were those of an investor "seeking to make" an investment in the United States.  A final, albeit controversial, argument that could have been advanced was that the U.S. is obliged to extend NAFTA protection to the wider category of "investments" defined in that country's bilateral investment treaties with non-NAFTA states, as a consequence of the "most favored nation" clause contained in NAFTA Article 1103 (which states that, "each Party shall accord to investors of another Party treatment no less favorable than it accords, in like circumstances, to investors of any other Party or of a non-Party with respect to the establishment, acquisition, expansion, management, conduct, operation, and sale or other disposition of investments.")  This wider category of investments would, based on the definitions of "investment" contained in a number of older U.S. BITs that remain in force (such as, for example, the U.S.-Congo BIT), likely be deemed to have included the "investment" made by Apotex in the United States.          

Conclusions 

In light of the Apotex award, U.S., Mexico and Canada-based companies with investments in other NAFTA signatory countries should be aware that the barriers to jurisdiction in NAFTA Investor-State proceedings are continuing to grow higher—particularly when compared to those in other treaty-based Investor-State arbitrations—though they are by no means insurmountable. Whilst host countries continue aggressively to fight NAFTA claims brought against them, successful outcomes for investors remain possible if the system is navigated wisely, for instance by ensuring that claims are brought under the most appropriate provisions of the treaty.  The tribunal's finding that Apotex's failure to exhaust local legal remedies in the U.S. would, in any event, have been fatal to its claim should also not be overlooked.  It is a cautionary tale which demonstrates that investors in the U.S., if a NAFTA claim is on the horizon, should be sure to file a pro forma certiorari appeal to the Supreme Court to ensure that all local U.S. legal remedies have been exhausted.  Jones Day has significant experience representing claimants in NAFTA proceedings and will continue closely to monitor developments in NAFTA jurisprudence.  We would be happy to discuss any questions or concerns you may have regarding the protection of investments in the United States, Canada or Mexico, including through the arbitration of investment disputes under NAFTA's Chapter Eleven.  

James Egerton-Vernon of the Washington Office assisted in the preparation of this Commentary.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Melissa Stear Gorsline
James Egerton-Vernon
 
In association with
Related Video
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
Accounting and Audit
Anti-trust/Competition Law
Consumer Protection
Corporate/Commercial Law
Criminal Law
Employment and HR
Energy and Natural Resources
Environment
Family and Matrimonial
Finance and Banking
Food, Drugs, Healthcare, Life Sciences
Government, Public Sector
Immigration
Insolvency/Bankruptcy, Re-structuring
Insurance
Intellectual Property
International Law
Litigation, Mediation & Arbitration
Media, Telecoms, IT, Entertainment
Privacy
Real Estate and Construction
Strategy
Tax
Transport
Wealth Management
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.